Survival Outcomes and the Role of Adjuvant Therapy Sequencing in Type II Uterine Cancer After Definitive Surgery

Gastric cancer has a poor prognosis. The majority of patients will relapse after definitive surgery, and 5-year survival after surgery remains poor. The role of adjuvant therapy in gastric cancer has been controversial given the lack of significant survival benefit in many randomized studies so far. The results of a large North American study (Gastrointestinal Cancer Intergroup Trial INT 0116) reported that postoperative chemoradiotherapy conferred a survival advantage compared with surgery alone, which has led to the regimen being adopted as a new standard of care. However, controversies still remain regarding surgical technique, the place of more effective and less toxic chemotherapy regimens, and the use of more modern radiation planning techniques to improve treatment delivery and outcome in the adjuvant and neoadjuvant setting. This article reviews the current status of the adjuvant treatment for gastric cancer including discussion on the research directions aimed at optimizing treatment efficacy. Issues such as the identification of patients who are more likely to benefit from adjuvant therapy are also addressed. Further clinical trials are needed to move towards better consensus and standardization of care.

Download Full-text

Role of hyperglucagonemia in maintenance of increased rates of hepatic glucose output in type II diabetics

Diabetes ◽

10.2337/diabetes.36.3.274 ◽

1987 ◽

Vol 36 (3) ◽

pp. 274-283 ◽

Cited By ~ 49

Author(s):

A. D. Baron ◽

L. Schaeffer ◽

P. Shragg ◽

O. G. Kolterman

Keyword(s):

Type Ii ◽

Hepatic Glucose Output ◽

Hepatic Glucose ◽

Type Ii Diabetics ◽

Glucose Output

Download Full-text

Role of lipid oxidation in pathogenesis of insulin resistance of obesity and type II diabetes

Diabetes ◽

10.2337/diabetes.36.11.1341 ◽

1987 ◽

Vol 36 (11) ◽

pp. 1341-1350 ◽

Cited By ~ 46

Author(s):

J. P. Felber ◽

E. Ferrannini ◽

A. Golay ◽

H. U. Meyer ◽

D. Theibaud ◽

...

Keyword(s):

Insulin Resistance ◽

Lipid Oxidation ◽

Type Ii Diabetes ◽

Type Ii

Download Full-text

The Role of Monoclonal Antibodies in Smoldering and Newly Diagnosed Transplant-Eligible Multiple Myeloma

Pharmaceuticals ◽

10.3390/ph13120451 ◽

2020 ◽

Vol 13 (12) ◽

pp. 451

Author(s):

Elena Zamagni ◽

Paola Tacchetti ◽

Paola Deias ◽

Francesca Patriarca

Keyword(s):

Multiple Myeloma ◽

Monoclonal Antibodies ◽

Immune System ◽

Survival Outcomes ◽

Newly Diagnosed ◽

Cellular Targets ◽

Recent Introduction

The recent introduction of monoclonal antibodies (MoAbs), with several cellular targets, such as CD-38 (daratumumab and isatuximab) and SLAM F7 (elotuzumab), differently combined with other classes of agents, has significantly extended the outcomes of patients with multiple myeloma (MM) in different phases of the disease. Initially used in advanced/refractory patients, different MoAbs combination have been introduced in the treatment of newly diagnosed transplant eligible patients (NDTEMM), showing a significant improvement in the depth of the response and in survival outcomes, without a significant price in terms of toxicity. In smoldering MM, MoAbs have been applied, either alone or in combination with other drugs, with the goal of delaying the progression to active MM and restoring the immune system. In this review, we will focus on the main results achieved so far and on the main on-going trials using MoAbs in SMM and NDTEMM.

Download Full-text